‘Watch China’ As Its Pharma Butterfly Flaps Its Wings
London Conference Told China’s Modernization Reforms Present ‘Paradigm Shift’
More affordable drug prices worldwide could result from China’s ongoing reforms in the life sciences sector, the FT Global Pharmaceutical and Biotechnology Conference hears.
You may also be interested in...
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.